The stability and antitumor activity of recycled (intravesical) mitomycin C

Stanley C. Hopkins, Robert G. Buice, Robert Matheny Jr, Mark S. Soloway

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Although intravesical mitomycin C (MMC) is effective in the treatment of superficial bladder cancer, its expense is a major factor limiting its use. These authors have analyzed the antitumor activity and stability of MMC following 2-hour intravesical instillation in consideration of recycling the drug or using a smaller dose over a longer retention time. The first voided urine samples from 11 patients who received 40 mg MMC intravesically were measured for MMC content by high performance liquid chromatography (HPLC). An average of 50% of the parent drug was recovered. MMC from the urine samples inhibited the growth of a transplantable murine transitional cell carcinoma, as effectively as stock drug. Moreover, MMC is relatively stable in urine at body temperature. These findings suggest that recovery and reuse of the intravesically administered drug is possible and if sterility and appropriate concentrations can be established for the initial and subsequent doses, the drug may be able to be recycled.

Original languageEnglish (US)
Pages (from-to)2063-2068
Number of pages6
Issue number10
StatePublished - May 15 1984

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The stability and antitumor activity of recycled (intravesical) mitomycin C'. Together they form a unique fingerprint.

Cite this